US 12,391,762 B2
Methods and compositions relating to GLP1R variants
Aaron Sato, Burlingame, CA (US); Pankaj Garg, Burlingame, CA (US); Qiang Liu, Palo Alto, CA (US); and Fumiko Axelrod, Palo Alto, CA (US)
Assigned to Twist Bioscience Corporation, South San Francisco, CA (US)
Filed by Twist Bioscience Corporation, South San Francisco, CA (US)
Filed on Aug. 25, 2021, as Appl. No. 17/412,139.
Claims priority of provisional application 63/081,801, filed on Sep. 22, 2020.
Claims priority of provisional application 63/070,734, filed on Aug. 26, 2020.
Prior Publication US 2022/0064313 A1, Mar. 3, 2022
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2869 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. An antibody or antibody fragment that binds to glucagon-like peptide-1 receptor (GLP1R) comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH), and the light chain comprises a light chain variable region (VL), wherein:
(a) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 441, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 620, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 799, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 978, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1157, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1336;
(b) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 534, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 713, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 892, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1071, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1250, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1429;
(c) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 561, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 740, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 919, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1098, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1277, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1456; or
(d) the VH comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 592, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 771, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 950, and wherein the VL comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 1129, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 1308, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 1487.